Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Clinical Trials in China

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University481 Fudan University478 Second Affiliated Hospital, Zhejiang University, School of Medicine401 Ruijin Hospital289 Peking Union Medical College Hospital279
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials in this register

19187 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
NCT05620680T Lymphoblastic Leukemia/Lymphoma
Shenzhen University General Hospital
Not applicable
20
Shenzhen
2022-10-01
Recruiting
Deeper Intubation Make Effects on Cervical Esophageal ESD
NCT06420258Carcinoma in Situ of Cervical Part of Esophagus
Fujian Provincial Hospital
Phase 4
40
Fuzhou
2022-10-01
Recruiting
Myopia Preventing With Distance-image Screen
NCT06088225Myopia, Progressive
Beijing Airdoc Technology Co., Ltd.
Not applicable
100
Beijing
2022-10-01
Recruiting
PK/PD of Caspofungin in Children Severe Infection
NCT04961593Pharmacokinetics, Infection, Fungal
DrugCaspofungin
Children's Hospital of Fudan University
Observational
60
Shanghai
2022-10-01
Active, closed
Dong Peng
Observational
300
Chongqing
2022-10-01
Recruiting
Second Affiliated Hospital of Nanchang University
Observational
200
Nanchang
2022-10-01
Recruiting
Ruijin Hospital
Not applicable
20
Shanghai
2022-10-01
Recruiting
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Not yet open
Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
NCT05510830Human Papilloma Virus Infection, Human Papilloma Virus Integration, Cervical Intraepithelial Neoplasia, Cervical Cancer
Tongji Hospital
Not applicable
250
Wuhan
2022-10
Active, closed
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Recruiting
Wuhan YZY Biopharma Co., Ltd.
Phase 1/2
116
Hangzhou
2022-09-30
Not yet open
Xijing Hospital
Phase 1/2
48
Xi'an
2022-09-30
Recruiting
Cell Free DNA in Mature B-cell Lymphoma
NCT04088422Mature B-Cell Lymphoma
Ruijin Hospital
Observational
320
Shanghai
2022-09-28
Active, closed
Hoffmann-La Roche
Phase 3
122
Beijing, Chengdu, Fuzhou, Jining, Shanghai, Wenzhou
2022-09-27
Active, closed
Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma
NCT07920757Extranodal NK/T-cell Lymphoma, Nasal Type
Fujian Medical University Union Hospital
Observational
50
Fuzhou
2022-09-27
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
200
Hangzhou
2022-09-27
Recruiting
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy
Fudan University
Phase 3
354
Shanghai
2022-09-27
Active, closed
Qilu Hospital of Shandong University
Phase 2
28
Jinan
2022-09-27
Active, closed
Allist Pharmaceuticals, Inc.
Phase 2
100
Changchun
2022-09-27
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4
210
Guangzhou
2022-09-27
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
40
Beijing, Haerbin, Qingdao
2022-09-26
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan
2022-09-23
Active, closed
AstraZeneca
Phase 1
14
Beijing, Shandong
2022-09-23
Active, closed
Peking University Third Hospital
Early Phase 1
9
Beijing
2022-09-23
Recruiting
INSIGHTFUL-FFR Clinical Trial
NCT05437900Coronary Artery Disease, Acute Coronary Syndrome
CoreAalst BV
Phase 4
2,500
Shanghai, Shandong, Sichuan
2022-09-22
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
102
Shanghai
2022-09-21
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
144
Jilin City
2022-09-20
Recruiting
Celgene
Phase 3
810
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Shijiazhuang
2022-09-20
Active, closed
Shen Feng
Observational
122
Shanghai
2022-09-20
Active, closed
Genmab
Phase 3
549
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2022-09-20
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Chaoyang, Chengdu, Hangzhou, Jinhua, Nanjing, Wuhan
2022-09-19
Recruiting
Peking Union Medical College Hospital
Not applicable
200
Beijing
2022-09-18
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
35
Hangzhou
2022-09-17
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
381
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Recruiting
InventisBio Co., Ltd
Phase 3
640
Beijing, Harbin
2022-09-15
Active, closed
AstraZeneca
Phase 3
594
Baoding, Beijing, Changsha, Chengdu, Deyang, Guangzhou, Hangzhou, Hefei
2022-09-15
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
278
Guangzhou
2022-09-15
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
324
Shanghai, Hangzhou
2022-09-15
Active, closed
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
NCT05520619Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
DrugsPaclitaxel, Cisplatin·Taxol·Tislelizumab
Sun Yat-sen University
Phase 2
114
Guangzhou
2022-09-15
Recruiting
Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
NCT05325034Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis, Hypercholesterolemia
Stephen Nicholls
Not applicable
2,000
Dalian
2022-09-15
Recruiting
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
NCT05652192Advanced Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
37
Hangzhou
2022-09-15
Recruiting
RenJi Hospital
Not applicable
484
Shanghai
2022-09-14
Active, closed
Shanghai East Hospital
Phase 1
36
Shanghai
2022-09-14
Active, closed
Biogen
Phase 2/3
450
Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang
2022-09-13
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou, Hefei, Jinhua
2022-09-13
Recruiting
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2022-09-13
Active, closed
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
NCT05399992Primary Hypercholesterolemia, Mixed Dyslipidemia
Novartis Pharmaceuticals
Observational
847
Shenzhen
2022-09-12
Recruiting
Children to Adults Mental and Psychosomatic Health Study (CAMPS)
NCT05621278Mental Health Wellness, Cognitive Function, Physical Symptoms
Peking University
Observational
400,000
Beijing
2022-09-11
Recruiting
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
NCT04728724Non-small Cell Lung Cancer Stage III
DrugSintilimab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2022-09-10
Active, closed
Fudan University
Phase 2
30
Shanghai
2022-09-10
Active, closed
Canwell Biotech Limited
Phase 1
27
Guangzhou
2022-09-09
Recruiting
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NCT05618041Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Not applicable
50
Taiyuan
2022-09-07
Active, closed
GlaxoSmithKline
Phase 3
110
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 2
168
Beijing
2022-09-06
Recruiting
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Zhengzhou, Wuhan
2022-09-05
Recruiting
Singlera Genomics Inc.
Observational
2,000
Hangzhou
2022-09-05
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
38
Shanghai
2022-09-05
Active, closed
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
NCT05522985Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
122
Tianjin
2022-09-02
Recruiting
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
NCT05824871Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)
DrugsSudapyridine·Bedaquiline
Shanghai Jiatan Pharmatech Co., Ltd
Phase 3
450
Beijing
2022-09-02
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
100
Guangzhou
2022-09-02
Recruiting
Dual-port Trans-subclavian Thyroid Endoscopic Surgery
NCT06398795Thyroid Neoplasms, Endoscopic Surgery
First Affiliated Hospital of Wenzhou Medical University
Not applicable
300
Wenzhou
2022-09-01
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
344
Quanzhou, Guangzhou, Shantou, Ganzhou, Changsha, Hengyang, Changchun, Shenyang
2022-09-01
Active, closed
Yi Junlin
Phase 3
414
Beijing
2022-09-01
Recruiting
Shanghai Municipal Hospital of Traditional Chinese Medicine
Not applicable
256
Shanghai
2022-09-01
Active, closed
The Affiliated Hospital of Qingdao University
Not applicable
368
Qingdao
2022-09-01
Recruiting
Mingzhao Xiao
Observational
800
Chongqing
2022-09-01
Recruiting
Teligene US
Phase 2
128
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Recruiting
RenJi Hospital
Not applicable
160
Shanghai
2022-09-01
Not yet open
Fujian Medical University
Phase 2
203
Fuzhou
2022-09-01
Recruiting
Pipeline Embolization for Intracranial Aneurysms
NCT06446778Efficacy, Self, Hemodynamic Instability, Stenosis, Aneurysm, Intracranial
Zhujiang Hospital
Observational
1,000
Guangzhou
2022-09-01
Recruiting
The Evolution and Prognosis of Moyamoya Disease
NCT05619068Moyamoya Disease, Revascularization, Cognitive Impairment, Functional Impairment
Chinese PLA General Hospital
Observational
300
Beijing
2022-09-01
Active, closed
Ningbo No. 1 Hospital
Not applicable
1,627
Ningbo
2022-09-01
Recruiting
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
NCT05495035Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
19
Hefei, Jinan, Tianjin, Shanghai
2022-09-01
Recruiting
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
NCT05514327Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy, Bridging Therapy
Peking Union Medical College Hospital
Not applicable
20
Beijing
2022-09-01
Recruiting
Second Affiliated Hospital of Nanchang University
Not applicable
112
Nanchang
2022-09-01
Recruiting
Second Affiliated Hospital of Nanchang University
Observational
7,100
Nanchang
2022-09-01
Active, closed
Ningbo No. 1 Hospital
Not applicable
331
Ningbo
2022-09-01
Recruiting
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
NCT06822413Cancer Diagnosis, Liver Cancer, Adult, Cancer Screening, Colorectal Cancer (CRC)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Nanchang, Shanghai, Hangzhou
2022-09-01
Recruiting
Shanghai 6th People's Hospital
Observational
200
Shanghai
2022-09-01
Recruiting
Shanghai Zhongshan Hospital
Phase 2
56
Shanghai
2022-09-01
Recruiting
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Recruiting
A Study on the Correlation Between Cotinine Levels and Aneurysm Wall Enhancement on HRMRI.
NCT06447714Cotinine Levels, Arterial Aneurysm Wall Enhancement on HRMRI
Zhujiang Hospital
Observational
450
Guangzhou
2022-09-01
Recruiting
Qilu Hospital of Shandong University
Observational
60
Jinan
2022-09-01
Recruiting
Study on the Mechanism of Eating Disorder
NCT05862389Anorexia Nervosa, Bulimia Nervosa
Peking University
Observational
750
Beijing
2022-09-01
Recruiting
First Affiliated Hospital of Guangxi Medical University
Phase 2
112
Nanning
2022-09-01
Recruiting
Olverembatinib for FGFR1-rearranged Neoplasms
NCT05521204Myeloproliferative Neoplasm, Acute Leukemia
DrugOlverembatinib
The First Affiliated Hospital of Soochow University
Phase 2
20
Suzhou
2022-09-01
Recruiting
LAAO Versus NOAC in Patients with AF and PCI
NCT05353140Atrial Fibrillation, Percutaneous Coronary Intervention
DrugsRivaroxaban·Clopidogrel·Aspirin
Xijing Hospital
Not applicable
1,386
Xi'an
2022-09-01
Not yet open
Xuanwu Hospital, Beijing
Not applicable
20
Beijing
2022-09
Active, closed
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
504
Hangzhou
2022-08-31
Recruiting
Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU
NCT05500118Leiomyoma, Uterine, High-Intensity Focused Ultrasound Ablation, Patients Decision Aids
Shenzhen Maternity & Child Healthcare Hospital
Observational
120
Shenzhen
2022-08-31
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing
2022-08-30
Recruiting
Xiao-nan He
Observational
10,000
Beijing
2022-08-30
Active, closed
Guiquan Zhu
Phase 1
50
Chengdu
2022-08-30
Not yet open
Pan Xiangbin
Not applicable
140
Beijing
2022-08-30
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache
DrugsErenumab·Eptinezumab
Beijing Tiantan Hospital
Observational
10,000
Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen
2022-08-29
Active, closed
National Health Research Institutes, Taiwan
Observational
300
2022-08-29
Recruiting
Hebei Senlang Biotechnology Inc., Ltd.
Not applicable
100
Beijingcun
2022-08-29
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Active, closed
LaNova Medicines Limited
Phase 1/2
392
Beijing
2022-08-26
Recruiting
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
NCT05240950Colorectal Cancer, Metastatic Liver Cancer
Changhai Hospital
Phase 1
18
Shanghai
2022-08-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
68
Beijing
2022-08-25
Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Jinan
2022-08-25
Recruiting
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Recruiting
Fudan University
Phase 1/2
52
Shanghai
2022-08-25
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Recruiting
Shanghai Virogin Biotech Co., Ltd.
Phase 1
30
Hangzhou
2022-08-23
Recruiting
Shanghai Zhongshan Hospital
Observational
600
Shanghai
2022-08-22
Active, closed
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Recruiting
The Cohort Study of Pediatric Cataract
NCT05472844Pediatric Cataract
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
5,000
Guangzhou
2022-08-22
Recruiting
The Registry Study of Genetic Alterations of Melanoma in Taiwan
NCT06952400Primary Melanoma of the Extremity
National Health Research Institutes, Taiwan
Observational
250
2022-08-22
Recruiting
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Observational
300
Fuzhou
2022-08-20
Recruiting
KSH01-TCRT Solid Tumors
NCT05539833TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
DrugKSH01
TCRx Therapeutics Co.Ltd
Early Phase 1
50
Nanning
2022-08-19
Recruiting
Henan Cancer Hospital
Phase 2
79
Zhengzhou
2022-08-19
Active, closed
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Active, closed
Janssen Research & Development, LLC
Phase 1
167
Chongqing, Guangzhou, Tianjin, Wuhan
2022-08-18
Active, closed
Nanfang Hospital, Southern Medical University
Phase 2
48
Guangzhou
2022-08-18
Active, closed
Beijing Mabworks Biotech Co., Ltd.
Phase 3
102
Beijing
2022-08-18
Recruiting
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Active, closed
Sun Yat-sen University
Phase 2
105
Guangzhou
2022-08-17
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
2022-08-17
Recruiting
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
NCT05549024Breast Cancer, Prostate Cancer, Brain Tumor, PET/CT Imaging
Drugs68Ga-RGD·Fluorodeoxyglucose
Peking Union Medical College Hospital
Early Phase 1
90
Beijing
2022-08-16
Recruiting
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
NCT06205992Cirrhosis, Liver Portal Hypertension
Shengjing Hospital
Observational
100
Shenyang
2022-08-16
Recruiting
3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
NCT05475015Cirrhosis, Liver, Portal Hypertension, Advanced Chronic Liver Disease
Shengjing Hospital
Observational
150
Shenyang
2022-08-16
Recruiting
Chongqing University Cancer Hospital
Phase 2
42
Chongqing
2022-08-15
Recruiting
Affiliated Hospital of Guangdong Medical University
Phase 3
180
Zhanjiang
2022-08-15
Recruiting
Latent Infection Freshmen Tracking for Tuberculosis
NCT07811518Latent Tuberculosis Infection (LTBI), Tuberculosis (TB)
Affiliated Hospital of Nantong University
Phase 4
3,000
Nantong, Meishan
2022-08-15
Recruiting
L & L Bio Co., Ltd., Ningbo, China
Phase 1
100
Shanghai
2022-08-12
Active, closed
Hrain Biotechnology Co., Ltd.
Early Phase 1
10
Nanchang
2022-08-12
Recruiting
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
NCT05484908Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
60
Guangzhou
2022-08-12
Recruiting
Zhengzhou University
Observational
100
Zhengzhou
2022-08-12
Active, closed
Beijing Tiantan Hospital
Early Phase 1
30
Beijing
2022-08-12
Recruiting
International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery
NCT05673499Congenital Disorders, Cerebral Desaturation, Neonatal Surgery
Children's Hospital of Philadelphia
Observational
900
Guangzhou, Shanghai, Shenyang, Sichuan
2022-08-12
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Guangzhou, Shanghai
2022-08-11
Active, closed
Novo Nordisk A/S
Phase 3
412
Beijing, Guangzhou, Liuzhou, Sanya, Zhengzhou, Wuhan, Changsha, Changchun
2022-08-10
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Recruiting
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Not applicable
538
Chengdu
2022-08-09
Recruiting
Keymed Biosciences Co.Ltd
Phase 1/2
48
Beijing
2022-08-09
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
423
Shanghai
2022-08-09
Recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
255
Guangzhou
2022-08-07
Not yet open
Chinese Academy of Medical Sciences
Phase 2/3
588
Beijing, Shenzhen
2022-08-06
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
381
Guangzhou
2022-08-04
Recruiting
China Medical University Hospital
Observational
6,000
2022-08-04
Recruiting
He Huang
Phase 1
29
Hangzhou
2022-08-04
Recruiting
He Huang
Phase 1
29
Hangzhou
2022-08-04
Recruiting
The Beijing Angle Closure Progression Study
NCT05563623Angle-Closure Glaucoma
Peking University People's Hospital
Observational
825
Beijing
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Recruiting
Zhejiang Cancer Hospital
Phase 2
100
Hanzhou, Ningbo
2022-08-03
Recruiting
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
NCT05468970Bone and Soft Tissue Tumors, Clinical Features
Henan Cancer Hospital
Observational
6,000
Zhengzhou
2022-08-03
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
30
Shanghai
2022-08-03
Recruiting
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Active, closed
AstraZeneca
Phase 3
341
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2022-08-03
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
DrugIDRX-42
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Beijing, Guangzhou, Wuhan
2022-08-03
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Recruiting
Chinese Colorectal Cancer Database
NCT05434026Colonic Cancer, Rectal Cancer, Prospective Studies
Beijing Friendship Hospital
Observational
200,000
Beijing
2022-08-03
Recruiting
Peking University First Hospital
Observational
3,000
Beijing, Guandong, Nanjing, Jinan
2022-08-01
Recruiting
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Active, closed
Tang-Du Hospital
Not applicable
30
Xi'an
2022-08-01
Not yet open
Xiaolu Li
Phase 4
116
Jinan
2022-08-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
100
Tianjin
2022-08-01
Recruiting
Beijing Friendship Hospital
Observational
1,000
Beijing, Tangshan
2022-08-01
Not yet open
Nanjing University of Traditional Chinese Medicine
Not applicable
90
Nanjing
2022-08-01
Recruiting
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
NCT05447208Preimplantation Genetic Testing, Growth Hormone, Age, Parental
DrugGrowth Hormone
ShangHai Ji Ai Genetics & IVF Institute
Phase 3
400
Shanghai
2022-08-01
Recruiting
National Cancer Center, China
Not applicable
30
Beijing
2022-08-01
Recruiting
Shengjing Hospital
Observational
200
Shenyang
2022-08-01
Recruiting
Children's Hospital of Fudan University
Not applicable
120
Shanghai
2022-08-01
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
300
Guangzhou
2022-08-01
Recruiting
Huashan Hospital
Observational
3,000
Shanghai
2022-08-01
Recruiting
Tianjin Medical University General Hospital
Not applicable
2,000
Tianjin
2022-08-01
Active, closed
Sun Yat-sen University
Phase 2
47
Guangzhou
2022-08-01
Recruiting
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
NCT05940961ALL, MRD-positive, Hematopoietic Stem Cell Transplantation
DrugInotuzumab Ozogamicin
Sheng-Li Xue, MD
Phase 2
42
Suzhou
2022-08-01
By invitation
Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
NCT07299123Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2022-08-01
Active, closed
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
NCT05306028Pancretic Cancer, Diabete Mellitus
DrugMetformin
Fudan University
Phase 2
20
Shanghai
2022-08-01
Recruiting
China HEalthy Aging and Dementia Study (HEAD)
NCT07912710Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD)
Fudan University
Observational
20,000
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan
2022-08-01
Recruiting
Xinqiao Hospital of Chongqing
Observational
20
Chongqing
2022-08-01
Recruiting
Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
NCT05392413Esophageal Squamous Cell Carcinoma, PD-1 Inhibitor
Nanfang Hospital, Southern Medical University
Observational
200
Guangzhou
2022-08-01
Recruiting
Fujian Medical University Union Hospital
Observational
9
Fuzhou
2022-08-01
Not yet open
Effects of Non-surgical Periodontal Therapy on Cardiovascular Risk
NCT05459727Cardiovascular Diseases, Periodontitis
Nanfang Hospital, Southern Medical University
Not applicable
376
Guangzhou
2022-08-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
28
Hanzhou
2022-08-01
Recruiting
Ting YANG
Observational
1,550
Beijing, Zunyi
2022-08-01
Recruiting
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
NCT05888909Diabetic Nephropathy Type 2, Diabetic Kidney Disease, Type 2 Diabetes
Chinese PLA General Hospital
Observational
2,000
Beijing
2022-08-01
Active, closed
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
NCT05468138MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
DrugXelox
Fudan University
Phase 2
94
Shanghai
2022-08-01
Recruiting
Tongji Hospital
Observational
604
Wuhan
2022-08-01
Recruiting
Fudan University
Phase 1/2
52
Shanghai
2022-08-01
Recruiting
Ming-an Yu
Observational
500
Beijing
2022-08-01
Recruiting
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
NCT05992597Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
Zhejiang Cancer Hospital
Phase 2
48
Hangzhou
2022-08-01
Recruiting
Henan Cancer Hospital
Phase 3
219
Zhengzhou
2022-08-01
Recruiting
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
NCT06006650Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
Tang-Du Hospital
Phase 2
114
Xi'an, Xi’an
2022-08-01
Recruiting
Guangdong Association of Clinical Trials
Observational
180
Foshan, Guangzhou, Shantou, Zhongshan
2022-08-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
140
Beijing
2022-08-01
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
132
Guangzhou
2022-08-01
Recruiting
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
172
Beijing, Nanchang, Chengdu
2022-08-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
64
Guangzhou
2022-08
Recruiting
Beijing Tongren Hospital
Phase 1
10
Beijing
2022-08
Recruiting
Efficacy of Probiotics in Patients With IBD
NCT05652621Ulcerative Colitis, Irritable Bowel Syndrome
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
200
Xinxiang
2022-07-31
By invitation
The First Affiliated Hospital with Nanjing Medical University
Not applicable
30
Nanjing
2022-07-30
Recruiting
Cancer Hospital of Guangxi Medical University
Observational
43
Nanning
2022-07-30
Recruiting
Sun Yat-sen University
Phase 2
194
Guangzhou
2022-07-29
Active, closed
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Recruiting
Janssen Research & Development, LLC
Phase 1/2
225
Dalian, Guangzhou, Hangzhou, Wuhan
2022-07-29
Recruiting
Shanghai Zhongshan Hospital
Phase 2
35
Shanghai
2022-07-28
Recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Observational
200
Shanghai
2022-07-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Recruiting
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT06909877Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
100
Chengdu
2022-07-27
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hanzhou
2022-07-26
Recruiting
Henan Cancer Hospital
Phase 2
43
Zhengzhou
2022-07-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,500
Quzhou, Taizhou
2022-07-22
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
125
Hangzhou
2022-07-22
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Haikou
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Recruiting
Tang-Du Hospital
Phase 2
64
Beijing, Changsha, Xi'an, Shanghai, Chengdu, Tianjin
2022-07-21
Active, closed
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Fuzhou, Xiamen, Lanzhou, Guangzhou, Yulin, Zhengzhou, Changsha, Nanchang
2022-07-20
Active, closed
Timing of Damage Control Orthopedic Surgery
NCT05785143The Precision Personal Timeline in Definitive Surgery Associated With Outcome
China Medical University Hospital
Observational
100
2022-07-20
Active, closed
Hereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort
NCT06512376Cerebral Small Vessel Diseases, Hereditary
Beijing Tiantan Hospital
Observational
100
Beijing
2022-07-19
Active, closed
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
8
Tianjin
2022-07-19
Recruiting
Fudan University
Observational
385
Hefei, Shijiazhuang, Zhengzhou, Nantong, Taishing, Taizhou, Xi'an, Tianjin
2022-07-18
Active, closed
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Not yet open
Intraperitoneal Lidocaine in Ovarian Cancer Surgery
NCT05450055Ovarian Cancer, Post Operative Pain
Peking University Third Hospital
Not applicable
60
Beijing
2022-07-18
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
300
Nanjing
2022-07-17
Active, closed
Sun Yat-sen University
Phase 2
84
Guangzhou
2022-07-15
Recruiting
China Medical University Hospital
Not applicable
50
2022-07-15
Active, closed
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05340270Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
Guangxi Medical University
Phase 2
150
Nanning
2022-07-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2022-07-14
Active, closed
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xi'an, Chengdu
2022-07-13
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Beijing, Shanghai
2022-07-13
Active, closed
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Recruiting
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
NCT05316935Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
DrugsGnRHa·Letrozole
Xiaojun Chen
Phase 2/3
80
Shanghai
2022-07-13
Active, closed
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
NCT06390904Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
DrugLetrozole
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Recruiting
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
NCT06379113Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
DrugLetrozole
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsOlaparib·Bevacizumab
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Recruiting
Peking University
Phase 2
30
Beijing
2022-07-12
Recruiting
Hrain Biotechnology Co., Ltd.
Phase 2
100
Shanghai, Wenzhou
2022-07-12
Recruiting
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
32
Beijing
2022-07-12
Active, closed
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
1,576
Hangzhou
2022-07-10
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,413
Hangzhou
2022-07-10
Recruiting
Nanjing First Hospital, Nanjing Medical University
Observational
150
Nanjing
2022-07-10
Recruiting
Sun Yat-sen University
Observational
11,625
Guangzhou
2022-07-10
Recruiting
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
NCT05461664Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
Xinhua Zhang, MD
Observational
74
Guangzhou
2022-07-10
Recruiting
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
NCT05464875Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
Xinhua Zhang, MD
Observational
74
Guangzhou
2022-07-09
Recruiting
Singlera Genomics Inc.
Observational
18,000
Beijing
2022-07-09
Active, closed
Daiichi Sankyo
Phase 3
586
Beijing, Changchun, Changsha, Chengdu, Chibi, Fuzhou, Guangzhou, Haidian
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Beijing, Nanjing, Shanghai
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Recruiting
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
180
Changchun
2022-07-07
Active, closed
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Recruiting
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
110
Suzhou
2022-07-06
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
635
Guangzhou
2022-07-06
Active, closed
Albireo, an Ipsen Company
Phase 3
180
Guangdong, Shanghai
2022-07-05
Recruiting
Sun Yat-sen University
Phase 3
766
Chongqing, Guangzhou, Hengyang, Shenyang, Xi'an, Nanchong
2022-07-05
Recruiting
State Key Laboratory of Subhealth Intervention Technology
Not applicable
120
Yichang, Changsha
2022-07-05
Recruiting
Chinese PLA General Hospital
Not applicable
200
Beijing
2022-07-04
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
120
Hangzhou
2022-07-02
Active, closed
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT06196827Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 1
9
Beijing, Shanghai
2022-07-02
Recruiting
Fudan University
Phase 2
198
Shanghai
2022-07-02
Recruiting
Peking Union Medical College Hospital
Not applicable
60
Beijing
2022-07-01
Recruiting
Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma
NCT06644352Siewert Type II Adenocarcinoma of Esophagogastric Junction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
236
Beijing
2022-07-01
Active, closed
National Health Research Institutes, Taiwan
Phase 2
51
2022-07-01
Recruiting
Zhejiang University
Observational
5,000
Hangzhou
2022-07-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Hangzhou
2022-07-01
Active, closed
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
DrugsKeytruda·Pembrolizumab
Peking Union Medical College Hospital
Phase 2
80
Beijing
2022-07-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
20,000
Guangzhou
2022-07-01
Recruiting
TAVR for Aortic Valve Disease
NCT05439863Aortic Valve Disease
Nanjing First Hospital, Nanjing Medical University
Observational
5,000
Nanjing
2022-07-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
1,199
Beijing
2022-07-01
Active, closed
ZhanYJ
Not applicable
150
Shanghai
2022-07-01
Not yet open
Shanghai Zhongshan Hospital
Not applicable
323
Shanghai
2022-07-01
Active, closed
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
66
Xiamen
2022-07-01
Recruiting
Shanghai Proton and Heavy Ion Center
Not applicable
48
Shanghai
2022-07-01
Recruiting
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
NCT05430971Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Immune Oncology Research Institute
Observational
200
2022-07-01
Recruiting
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
NCT05597709Type 2 Diabetes Mellitus in Remission, Metabolic Associated Fatty Liver Disease
Wuxi Hisky Medical Technology Co Ltd
Observational
2,900
Nanjing
2022-07-01
Recruiting
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
NCT05476627Chronic Kidney Diseases, Hypertension, Diabetes Mellitus, Hyperuricemia
Peking Union Medical College Hospital
Observational
200
Beijing
2022-07-01
Recruiting
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NCT05444478Hepatocellular Carcinoma, Microwave Ablation, Liver Cancer, Lenvatinib
DrugLenvatinib
Sun Yat-sen University
Not applicable
274
Changsha
2022-07-01
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
432
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei, Guangzhou
2022-07-01
Recruiting
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
NCT05735145Uterine Cervical Neoplasms, Chemoradiotherapy, Adjuvant Chemotherapy
DrugPaclitaxel
Fourth Affiliated Hospital of Guangxi Medical University
Phase 3
108
Liuzhou
2022-07-01
By invitation
The Anorectal Center of Nanjing Hospital of Traditional Chinese Medicine
Early Phase 1
90
Nanjing
2022-07-01
Active, closed
Qiang Xu
Observational
272
Nanchang
2022-07-01
Not yet open
Observation of the Natural Course of Age-related Macular Degeneration
NCT05418231Dry Age-related Macular Degeneration, Macular Degeneration, Dry
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
500
Shanghai
2022-07
Not yet open
Lai Wei
Observational
1,000
Beijing
2022-07
By invitation
The Gut Microbiota and Metabolites in HFpEF
NCT06645535HFpEF - Heart Failure With Preserved Ejection Fraction
The First Affiliated Hospital with Nanjing Medical University
Observational
300
Naning
2022-06-30
Active, closed
Cloudbreak Therapeutics, LLC
Phase 3
660
Beijing, Chengdu, Haikou, Hengyang, Kunming, Nanchang, Qingdao, Wenzhou
2022-06-30
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
18
Guangzhou, Changsha
2022-06-30
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Hefei, Beijing, Chaoyang, Chongqing, Harbin, Zhengzhou, Wuhan, Xuzhou
2022-06-30
Recruiting
Fudan University
Phase 2
90
Shanghai
2022-06-30
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
DrugTucatinib
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Active, closed
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma
DrugsCadonilimab·Lenvatinib
Akeso
Phase 2
60
Beijing, Guangzhou, Zhengzhou, Changsha, Jinan
2022-06-28
Recruiting
Ofatumumab in AQP4-IgG Seropositive NMOSD
NCT05504694Neuromyelitis Optica Spectrum Disorder
DrugOfatumumab
Tang-Du Hospital
Phase 1/2
5
Xi'an
2022-06-28
Active, closed
Akeso
Phase 2
254
Guanzhou
2022-06-27
Recruiting
Chongqing University Cancer Hospital
Not applicable
1,956
Chongqing
2022-06-27
Active, closed
Observational Study in Multiple System Atrophy
NCT05453058Multiple System Atrophy
H. Lundbeck A/S
Observational
90
Beijing, Changsha, Chengdu, Shanghai, Suzhou
2022-06-25
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2/3
124
Suzhou
2022-06-25
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
1,700
Guangzhou, Zhuhai
2022-06-24
Active, closed
Celgene
Phase 3
939
Changsha, Nanchang, Xi'an, Shanghai, Taiyuan, Wenzhou, Beijing, Changchun
2022-06-23
Active, closed
Sanofi
Phase 3
531
Beijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanning, Qingdao, Shenyang
2022-06-23
Active, closed
Sun Yat-sen University
Phase 1/2
46
Beijing, Dalian, Guangzhou, Nanchang
2022-06-23
Active, closed
Beckman Coulter, Inc.
Observational
2,200
Beijing, Chengdu, Hangzhou
2022-06-23
Recruiting
Peking University Cancer Hospital & Institute
Not applicable
50
Beijing
2022-06-23
Active, closed
NAC for Treatment-Resistant OCD and Other Related Disorders
NCT06956157Obsessive Compulsive Disorder (OCD)
DrugN-Acetylcysteine
Guangdong Provincial People's Hospital
Phase 4
90
GuangDong
2022-06-22
Active, closed
Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC
NCT05459415Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Resection Margin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
54
Wuhan
2022-06-22
Recruiting
Deep Brain Stimulation for Idiopathic Craniofacial Dystonia: GPi or STN
NCT05416905Craniofacial Dystonia, Deep Brain Stimulation
Beijing Tiantan Hospital
Not applicable
110
Beijing
2022-06-22
Active, closed
Akeso
Phase 3
636
Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2022-06-21
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
DrugsUtidelone·Docetaxel
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
102
Beijing
2022-06-21
Active, closed
Singlera Genomics Inc.
Observational
800
Beijing, Chengdu, Guangzhou, Haerbin, Shanghai, Shenzhen, Taiyuan
2022-06-20
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
60
Zhengzhou
2022-06-20
Active, closed
Guangdong Association of Clinical Trials
Phase 3
192
Guangzhou
2022-06-20
Active, closed
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
NCT05363800Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
74
Zhengzhou, Shengyang, Hangzhou
2022-06-17
Active, closed
Efficacy of Triple-Combination Therapy in Severe PAH-CHD
NCT06196801Congenital Heart Disease, Pulmonary Arterial Hypertension
Guangdong Provincial People's Hospital
Observational
80
Guangzhou
2022-06-17
Active, closed
SQ-Kyrin-T First-in-man Feasibility Study
NCT06605313Tricuspid Regurgitation
Shanghai Shenqi Medical Technology Co., Ltd
Not applicable
12
Kunming
2022-06-16
Recruiting
Guangzhou University of Traditional Chinese Medicine
Not applicable
82
Guangzhou
2022-06-15
Recruiting
Adagene Inc
Phase 1/2
186
Fuzhou, Guangzhou, Hong Kong
2022-06-15
Not yet open
Peking University Third Hospital
Not applicable
180
Beijing
2022-06-15
Recruiting
The Jinling Cohort
NCT06011694Cancer, Multi Cancer Early Screening, Liquid Biopsy
Nanjing Shihejiyin Technology, Inc.
Observational
15,000
Nanjing
2022-06-15
Active, closed
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
12
Wuhan
2022-06-14
Recruiting
Shengjing Hospital
Observational
100
Shenyang
2022-06-14
Active, closed
Genmab
Phase 2
264
Beijing, Shanghai
2022-06-14
Recruiting
RemeGen Co., Ltd.
Phase 3
452
Beijing
2022-06-14
Active, closed
Sichuan Clover Biopharmaceuticals, Inc.
Phase 1
36
Chengdu
2022-06-14
Recruiting
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
NCT05316493Atypical Endometrial Hyperplasia, Fertility Issues, Overweight and Obesity
DrugMegestrol Acetate
Xiaojun Chen
Phase 2/3
172
Shanghai
2022-06-13
Active, closed
Bayer
Observational
4,613
Many Locations
2022-06-13
Recruiting
A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery
NCT05242419Injection, Non-cardiac Surgery, Delirium in Old Age, Post Operative Delirium
DrugHuperzine A
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
40
Wenzhou
2022-06-10
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
254
Beijing, Nanjing
2022-06-10
By invitation
Biogen
Phase 3
864
Beijing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Haikou, Shijiazhuang, Changsha
2022-06-10
Recruiting
Peking University
Not applicable
102
Beijing
2022-06-10
Active, closed
Sun Yat-sen University
Phase 3
450
Zhanjiang, Wuzhou, Guiyang, Changsha
2022-06-10
Recruiting
Zhu Weiming
Not applicable
138
Nanjing
2022-06-09
Recruiting
BeBetter Med Inc
Phase 3
330
Beijing
2022-06-09
Active, closed
Merck Sharp & Dohme LLC
Phase 1
12
Guangzhou, Zhengzhou, Changsha, Tianjin
2022-06-09
Active, closed
Fudan University
Not applicable
56
Shanghai
2022-06-09
Recruiting
TYK Medicines, Inc
Phase 3
680
Changsha, Shanghai
2022-06-08
Active, closed
Effect of FMD on Colorectal Cancer Patients
NCT05384444Fasting Mimicking Diet, Colorectal Cancer
Fudan University
Not applicable
602
Shanghai
2022-06-08
Recruiting
Astellas Pharma Inc
Phase 1
681
Beijing, Xuhui District, Shanghai
2022-06-08
Active, closed
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Recruiting
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
NCT05397769Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1
DrugEnvafolimab
Sun Yat-sen University
Phase 2
36
Guangzhou
2022-06-08
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Guangzhou, Zhengzhou, Wuhan, Shanghai, Hangzhou
2022-06-07
Recruiting
Antengene Therapeutics Limited
Phase 1
98
Chongqing, Guangzhou
2022-06-07
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
272
Beijing
2022-06-07
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
295
Beijing
2022-06-07
By invitation
Preservation of Venous Valvular Function After PMT for Acute DVT
NCT05588284Acute Deep Venous Thrombosis of Femoral Vein (Disorder)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Not applicable
100
Chuzhou, Shanghai, Taizhou
2022-06-06
Recruiting
Qianfoshan Hospital
Not applicable
134
Jinan
2022-06-06
Recruiting
The Dampness Syndrome of Chinese Medicine Cohort Study
NCT05315895Chronic Disease, Cancer, Dementia Alzheimers, Metabolic Disease
Guangzhou University of Traditional Chinese Medicine
Observational
100,000
Guangzhou
2022-06-06
Recruiting
NOACs Use in AF or VTE (SUNSHINE Registry)
NCT05378308Atrial Fibrillation, Venous Thromboembolism, Oral Anticoagulant
Henan Provincial People's Hospital
Observational
5,000
Zhengzhou
2022-06-06
Active, closed
Chinese University of Hong Kong
Observational
1,350
Hong Kong
2022-06-06
Recruiting
State Key Laboratory of Subhealth Intervention Technology
Not applicable
120
Yichang, Changsha
2022-06-05
Active, closed
Shanghai Zhongshan Hospital
Not applicable
1,016
Shanghai
2022-06-05
Active, closed
National Vaccine and Serum Institute, China
Phase 3
13,500
Hechi, Hezhou, Lianyuan, Wuxi, Yongji, Yuncheng, Mianyang, Neijiang
2022-06-04
Recruiting
Fujian Medical University
Phase 2
68
Fuzhou
2022-06-03
Recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
NCT05252078Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases, Gastrointestinal Neoplasms
DrugsAnlotinib hydrochloride·Benmelstobart
Jiangxi Provincial Cancer Hospital
Phase 2
30
Nanchang
2022-06-02
Active, closed
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Active, closed
AMP SCZ® Observational Study: PREDICT-DPACC
NCT05905003Clinical High Risk, Psychosis, Remission, Conversion
Brigham and Women's Hospital
Observational
2,617
Shanghai
2022-06-02
Recruiting
Qilu Hospital of Shandong University
Not applicable
110
Jinan
2022-06-01
Recruiting
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
NCT05227534Cancer, Early Detection of Cancer, Circulating Cell-free DNA
Guangzhou Burning Rock Dx Co., Ltd.
Not applicable
12,500
Chengdu
2022-06-01
Recruiting
Zhujiang Hospital
Observational
40
Guangzhou
2022-06-01
Active, closed
A Multi-center Retrospective Study of INO Treating B-ALL
NCT07238907Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL), Inotuzumab Ozogamicin, Venetoclax
DrugInotuzumab Ozogamicin
Ruijin Hospital
Observational
102
Shanghai
2022-06-01
By invitation
Shanghai 10th People's Hospital
Not applicable
300
Shanghai
2022-06-01
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Not applicable
72
Nanjing
2022-06-01
Recruiting
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
NCT05766449Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,000
Nanjing
2022-06-01
Active, closed
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors
NCT05385692Locally Advanced or Metastatic Digestive Tract Tumors, Solid Tumor
DrugBL-M02D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Guangzhou
2022-06-01
Recruiting
Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an
NCT05424978Acute Ischemic Stroke, Thrombolysis, Endovascular Treatment
Xi'an No.3 Hospital
Observational
3,600
Xi'an
2022-06-01
Recruiting
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase 1
288
Beijing, Changsha, Ganzhou, Hangzhou, Hanzhou, Linyi, Nanjing
2022-06-01
Recruiting
Renal Nerve Denervation(RDN) and Renal Function
NCT05612906Effects of RDN on Renal Function
Zhengrong Huang
Observational
50
Xiamen
2022-06-01
Active, closed
The First Affiliated Hospital of Anhui Medical University
Phase 2
50
Hefei
2022-06-01
Recruiting
Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment
NCT05326399Liver Transplantation, Renal Insufficiency, Chronic
RenJi Hospital
Observational
369
Shanghai
2022-06-01
Active, closed
Intracranial Arterial Stenosis in Young Patients
NCT05844176Intracranial Arterial Stenosis
Capital Medical University
Observational
500
Suzhou, Shijiazhuang, Beijing, Zhengzhou
2022-06-01
By invitation
Qiu Guoqin
Phase 1/2
30
Hangzhou
2022-06-01
Recruiting
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
NCT05410717Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent, CAR NK
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
200
Guangzhou
2022-06-01
Not yet open
Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics
NCT05369689Stereotactic Radiosurgery, Spinal Tumor, Radiomics, Prognosis
Zhuang Hongqing
Observational
300
Beijing
2022-06-01
Not yet open
Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes
NCT05294653Atherosclerotic Cardiovascular Disease, Childhood Diabetes Mellitus, Juvenile Diabetes
Shanghai Jiao Tong University School of Medicine
Observational
300
Shanghai
2022-06-01
Recruiting
Sun Yat-sen University
Observational
500
Guangzhou
2022-06-01
Recruiting
Sun Yat-sen University
Not applicable
264
Guangzhou
2022-06-01
Recruiting
The Third Xiangya Hospital of Central South University
Observational
600
Changsha
2022-06-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
61
Shanghai
2022-06-01
By invitation
Shenzhen People's Hospital
Observational
60
Shenzhen
2022-06-01
Recruiting
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
NCT05566002Pulmonary Hypertension, Pulmonary Arterial Hypertension
Chinese Pulmonary Vascular Disease Research Group
Observational
2,000
Beijing
2022-06-01
Recruiting
Peking University First Hospital
Observational
366
Beijing
2022-06-01
Not yet open
Peking University Third Hospital
Observational
500
Beijing
2022-06
Not yet open
Umbrella Biomarker-Guided Therapy in NPC
NCT04605562Nasopharyngeal Carcinoma
DrugsGalunisertib·Palbociclib
Sun Yat-sen University
Phase 2
206
Guangzhou
2022-06
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2022-06
Recruiting
Assessment of Brain Cognitive Impairment in Breast Cancer
NCT05305092Breast Cancer, Chemo-brain, Endocrine Therapy
Tang-Du Hospital
Observational
90
Xi'an
2022-05-31
Recruiting
Fuzhou General Hospital
Phase 2
93
Fuzhou
2022-05-31
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Hohhot, Jinan, Nanchang
2022-05-30
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 1
15
Tianjin
2022-05-30
Recruiting
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2
267
Zhengzhou, Chengdu, Hangzhou, Beijing
2022-05-30
Recruiting
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT05518253Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
Weijia Fang, MD
Phase 1
30
Hangzhou
2022-05-30
Active, closed
Biotheus Inc.
Phase 2
99
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nanchang
2022-05-27
Active, closed
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
DrugLorlatinib
CStone Pharmaceuticals
Phase 2
70
Guangzhou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2022-05-27
Recruiting
Shenzhen Hemogen
Early Phase 1
3
Shenzhen
2022-05-27
Recruiting
A Prognostic Model for Drug-induced Liver Injury in China
NCT05060289Drug-induced Liver Injury
Beijing Friendship Hospital
Observational
3,000
Beijing, Dalian, Guangxi, Hebei, Jiaozuo, Lanzhou, Qingdao, Qinghai
2022-05-25
Recruiting
Chinese University of Hong Kong
Phase 2
110
Wenzhou
2022-05-25
Recruiting
Beijing Tiantan Hospital
Observational
200
Beijing, Zhengzhou, Nanjing
2022-05-25
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
Guangzhou, Zhengzhou
2022-05-25
Recruiting
Nanjing First Hospital, Nanjing Medical University
Observational
5,000
Nanjing
2022-05-24
Recruiting
Huai'an First People's Hospital
Not applicable
34
Huai'an
2022-05-24
Recruiting
Huashan Hospital
Phase 3
1,050
Guiyang, Kaili, Liupanshui, Zunyi, Shanghai
2022-05-23
Recruiting
Nanjing First Hospital, Nanjing Medical University
Not applicable
180
Nanjing
2022-05-23
Recruiting
Grit Biotechnology
Phase 1
31
Beijing, Chongqing, Shanghai, Chengdu, Tianjin
2022-05-23
Active, closed
Caigang Liu
Phase 2/3
136
Shenyang
2022-05-23
Active, closed
xiaohua li
Observational
176
Xi'an
2022-05-22
Recruiting
Patient's Whole Process Follow-up Management(HOPE-1)
NCT05339568Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC
Qianfoshan Hospital
Observational
1,268
Jinan
2022-05-22
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
110
Guangzhou
2022-05-20
Recruiting
Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.
NCT06097065Prediabetes, Diabetes Mellitus, Gestational Diabetes Mellitus, Proteomics
Zhujiang Hospital
Observational
2,860
Guangzhou
2022-05-20
Recruiting
Multicenter Study of Fulminant Type 1 Diabetes in China
NCT05593081Diabetes Mellitus, Type 1
Second Xiangya Hospital of Central South University
Observational
240
Quanzhou, Guangzhou, Nanning, Zunyi, Haikou, Changsha, Yancheng, Nanchang
2022-05-20
Active, closed
Henan Cancer Hospital
Phase 2
120
Zhengzhou
2022-05-20
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
82
Bengbu, Guangzhou, Guilin, Wuhan, Yueyang, Changchun, Hangzhou
2022-05-20
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
312
Tianjin
2022-05-19
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Recruiting
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
NCT06173076Autoimmune Encephalitis, Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Shen Chun-Hong
Observational
60
Hangzhou
2022-05-18
Active, closed
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
214
Shanghai
2022-05-18
Active, closed
Istituto Giannina Gaslini
Observational
272
Hangzhou
2022-05-18
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
122
Jinan
2022-05-18
Active, closed
Sun Yat-sen University
Phase 2
150
Guangzhou
2022-05-17
Active, closed
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Recruiting
Xijing Hospital
Not applicable
1,060
Xi'an
2022-05-16
Active, closed
AstraZeneca
Phase 3
644
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-05-16
Active, closed
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2022-05-15
Active, closed
Enlight Medical Technologies (Shanghai) Co., Ltd
Not applicable
102
Beijing
2022-05-15
Recruiting
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
NCT05371353HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
Shanghai Bovax Biotechnology Co., Ltd.
Observational
600
Yangchun, Mianyang
2022-05-14
Active, closed
Henan Cancer Hospital
Phase 2
42
Zhengzhou
2022-05-13
Active, closed
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
526
Shanghai
2022-05-13
Recruiting
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
NCT05498064Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase I1171N, Ensartinib
DrugEnsartinib
Peking Union Medical College Hospital
Observational
490
Beijing
2022-05-13
Active, closed
Sun Yat-sen University
Phase 3
452
Guangzhou
2022-05-11
Active, closed
Eli Lilly and Company
Phase 1
260
Beijing, Nanchang, Shanghai
2022-05-11
Recruiting
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
NCT07400224Hyperthyroidism, Autoimmune, Cardiovascular Abnormalities, Malignant Tumor
Peking Union Medical College Hospital
Phase 1/2
600
Beijing
2022-05-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,590
Liuzhou, Louxing District, Guang’an, Mianyang
2022-05-07
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
146
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang
2022-05-06
Recruiting
Ying Lin
Phase 2
66
Guangzhou
2022-05-06
Recruiting
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Recruiting
Incyte Corporation
Phase 2
98
Beijing, Shanghai
2022-05-05
Active, closed
Akeso
Phase 1/2
154
Hangzhou
2022-05-04
Recruiting
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
NCT06128148Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms
Guangzhou JOYO Pharma Co., Ltd
Phase 1
101
Guangzhou
2022-05-04
Recruiting
Actelion
Phase 3
280
Beijing, Changsha, Nanjing, Qingdao, Shanghai, Xi'an
2022-05-04
Active, closed
Sanofi
Phase 3
104
Beijing, Chengdu, Guangzhou, Shanghai
2022-05-03
Recruiting
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
NCT04657861Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Zhejiang University
Early Phase 1
36
Hangzhou
2022-05-03
Active, closed
The First Affiliated Hospital of Soochow University
Observational
1,000
Suzhou
2022-05-03
Active, closed
The First Affiliated Hospital of Zhengzhou University
Phase 2
36
Jiaozuo, Luoyang
2022-05-02
Recruiting
West China Hospital
Observational
1,300
Sichuan
2022-05-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2022-05-01
Not yet open
Fudan University
Phase 2
42
Shanghai
2022-05-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
1,362
Tianjin
2022-05-01
Recruiting
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
NCT05341492EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
Second Affiliated Hospital of Guangzhou Medical University
Early Phase 1
30
Guangzhou
2022-05-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
80
Shijiazhuang
2022-05-01
Recruiting
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
NCT05349552Radiotherapy, Thoracic Cancer, Safety and Efficacy
Peking University Third Hospital
Observational
120
Beijing
2022-05-01
Recruiting
Translational Immunodiagnostics in Stroke (TrImS)
NCT05300997Acute Ischemic Stroke, Haemorrhagic Stroke, Transient Ischemic Attacks, Cardioembolic Stroke
The University of Hong Kong
Observational
650
Hong Kong
2022-05-01
Recruiting
Beijing Tiantan Hospital
Observational
400
Beijing
2022-05-01
Recruiting
Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction
NCT05356520Siewert Type II Adenocarcinoma of Esophagogastric Junction
Xijing Hospital of Digestive Diseases
Not applicable
212
Xi'an
2022-05-01
Recruiting
Shanghai 10th People's Hospital
Observational
5,000
Shanghai
2022-05-01
Recruiting
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
NCT05731258Breast Cancer, Liposomal Doxorubicin, Efficacy, Safety
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2022-05-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
17
Guangzhou
2022-05-01
Recruiting
Qilu Hospital of Shandong University
Observational
2,200
Jinan
2022-05-01
Recruiting
Second Xiangya Hospital of Central South University
Observational
400
Changsha
2022-05-01
Recruiting
Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
NCT05189054Stereotactic Body Radiation Therapy, Irradiation; Reaction, Thoracic Tumor, Recurrent Cancer
Peking University Third Hospital
Observational
40
Beijing
2022-05-01
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
144
Guangzhou
2022-05-01
Recruiting
Shanghai Zhongshan Hospital
Observational
6,000
Xiamen, Guangzhou, Zhengzhou, Wuhan, Jiangyin, Wuxi, Yangzhou, Yixing
2022-05-01
Recruiting
Third Military Medical University
Observational
350
Chongqing
2022-05-01
Recruiting
CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
NCT05433467Cirrhosis, Liver, Hepatocellular Carcinoma
Northern Jiangsu People's Hospital
Not applicable
5
Yangzhou
2022-05-01
Not yet open
Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA
NCT04698330Type 1 Diabetes Mellitus, Autoimmune Diabetes
DrugBerberine
Second Xiangya Hospital of Central South University
Phase 4
240
Changsha
2022-05
Recruiting
Children's Hospital of Fudan University
Observational
5,000
Shanghai
2022-04-30
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4
2,400
Harbin
2022-04-30
Recruiting
Xiangya Hospital of Central South University
Observational
200
Changsha
2022-04-30
Recruiting
Peking Union Medical College Hospital
Observational
20,000
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Hangzhou
2022-04-29
Recruiting
Observational Study About Patients Diagnosed With NAFLD
NCT05625750Nonalcoholic Fatty Liver Disease
Xiangya Hospital of Central South University
Observational
500
Changsha
2022-04-27
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Recruiting
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
340
Beijing
2022-04-26
Active, closed
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Ma’anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Recruiting
Sun Yat-sen University
Observational
200
Guangzhou
2022-04-25
Active, closed
Hoffmann-La Roche
Phase 3
208
Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou
2022-04-25
Active, closed
Sun Yat-sen University
Phase 2
46
Guangzhou
2022-04-24
Recruiting
Super-Hypofractionated Partial Breast Irradiation
NCT06615466Breast Cancer, Radiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2022-04-22
Recruiting
Keymed Biosciences Co.Ltd
Phase 1/2
248
Chengdu, Shanghai
2022-04-21
Recruiting
Multiomics Tumor Evolution Model of NSCLC
NCT05352035Non-small Cell Lung Cancer
Peking University People's Hospital
Observational
300
Beijing
2022-04-20
Recruiting
Sichuan Cancer Hospital and Research Institute
Phase 2
170
Chengdu
2022-04-20
By invitation
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Active, closed
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
NCT05345522Idiopathic Multicentric Castleman's Disease
Beijing VDJBio Co., LTD.
Phase 2
25
Beijing, Chengdu
2022-04-18
Recruiting
BeijngFH Health Cohort Study
NCT05546086Non-Alcoholic Fatty Liver Disease
Beijing Friendship Hospital
Observational
8,103
Beijing
2022-04-18
Active, closed
Sanofi
Phase 3
43
Taipei, Beijing, Guangzhou, Shanghai
2022-04-18
Recruiting
Sun Yat-sen University
Phase 3
556
Guangzhou
2022-04-17
Recruiting
China Gender-affirming Hormone Therapy Study
NCT05318755Transgender, Gender Incongruence
DrugTestosterone
Peking University Third Hospital
Observational
240
Beijing
2022-04-16
Recruiting
Xiang Wei
Not applicable
1,000
Wuhan
2022-04-15
Recruiting
Peking Union Medical College Hospital
Not applicable
50
Beijing
2022-04-15
Recruiting
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
NCT06706713Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
DrugBEBT-109
BeBetter Med Inc
Phase 2
200
Guangzhou, Changsha
2022-04-15
Recruiting
Chongqing University Cancer Hospital
Not applicable
40
Chongqing
2022-04-15
Active, closed
Eli Lilly and Company
Phase 3
925
Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha
2022-04-14
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Recruiting
Cogent Biosciences, Inc.
Phase 3
482
2022-04-14
Recruiting
Chongqing University Cancer Hospital
Not applicable
40
Chongqing
2022-04-13
By invitation
Xuanwu Hospital, Beijing
Observational
500
Beijing
2022-04-13
Rows per page Showing 16501–17000 of 19187
Previous 32 33 34 35 36 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china?page=34

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,790 of the 19,187 studies in this register are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 3,998 have not yet opened recruitment, 2,715 are active but closed to new participants, and 684 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (423) Advanced Solid Tumors (187) Colorectal Cancer (179) Gastric Cancer (175) Hepatocellular Carcinoma (154) Advanced Solid Tumor (153) Non-Small Cell Lung Cancer (145) Solid Tumor (142) Acute Ischemic Stroke (140) Lung Cancer (135) Non-small Cell Lung Cancer (132) Pancreatic Cancer (131) Multiple Myeloma (128) Coronary Artery Disease (122) Prostate Cancer (110)
→

Browse trials by site location

Beijing (5576) Shanghai (3879) Guangzhou (3345) Hangzhou (1819) Wuhan (1343) Chengdu (1307) Nanjing (1211) Changsha (1154) Chongqing (1078) Fuzhou (1040) Tianjin (934) Zhengzhou (931) Hefei (896) Jinan (783) Changchun (639)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.